Mechanistically, the activation of FXR ameliorates intestinal inflammation and inhibits tumor growth associated with colitis by modulating the recruitment, polarization, and interaction of intestinal macrophages with Th17 cells. This evidence concerns the gene NR1H4 and neoplasm.